top of page


Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

Biopharma Planned Trials & Regulatory Updates

Future clinical trials and regulatory activity..👇

Ventyx Biosciences

🔬 Initiate a Ph3 trial of VTX002 treating UC in H2 2024. 

Lytix Biopharma

🔬 Initiate an investigator-led Ph2 study for a neoadjuvant in melanoma patients in H1 2024. 

GRI Bio 

🔬 Received UK-MHRA authorization to conduct Ph2a biomarker study evaluating GRI-0621 in IPF. 


🔬 CTA cleared by the UK-MHRA to initiate Ph2 CONNECT2-EDO51 trial of PGN-EDO51 for the treatment of DMD. 

Nektar Therapeutics 

🔬 Initiated a Ph2b study evaluating Rezpegaldesleukin in patients with alopecia areata.

Atara Biotherapeutics

🔬 FDA cleared IND application for a Ph1 trial of ATA3219 as treatment for lupus nephritis in H2 2024. 

Cullinan Oncology 

🔬 IND application cleared for a Ph1 trial of CLN-619 for relapsed/refractory multiple myeloma.

Precision BioSciences & iECURE

🔬 UK-MHRA approved to expand the Ph1/2 trial of ARCUS gene editing program in OTC deficiency. 

Quoin Pharmaceuticals 

🔬 Received FDA clearance to recruit teen subjects into both ongoing Netherton syndrome clinical studies.

Oncolytics Biotech

🔬 Protocol amendment filed to initiate a new pancreatic cancer GOBLET cohort supported by PanCAN.

Achieve Life Sciences

🔬 Open-label exposure trial expected to initiate in Q2 2024.

Crossbow Therapeutics

🔬 Selected first development candidate (CBX-250) from portfolio of next-generation T-cell engagers.

Iovance Biotherapeutics 

📋 FDA lifted clinical hold on the IOV-LUN-202 registrational trial in NSCLC.

Calliditas Therapeutics

📋 Granted additional seven year orphan drug exclusivity period for TARPEYO®.

Verastem Oncology 

📋 FDA granted Orphan Drug Designation to Avutometinib +/- Defactinib in recurrent low-grade serous ovarian cancer.


Interested in these updates? Get the full update each week → 

Article History:

RF, DV (03/06/24)


bottom of page